Utvecklingen inom portföljbolagen visar fortsatt på en bra utveckling under det första kvartalet.
Redeye provides a comment following Magle Group’s announcement of the acquisition of Swedish medtech...
Redeye provides a research update following the Q1 report published by Lipum earlier today.
Following low volumes in the previous Q4, Hansa’s Q1 is well above the rolling 12m average, and the ...
Net sales and EBIT were below market consensus (LSEG) in Q1.
Sales -7%, adj. EBIT -2.7m vs. ABGSCe Gross margin at record high level 48% (45%) Performance Chemic...
Sales +6% and EBIT -8% vs. ABGSCe Order bookings 11% better than ABGSCe Slightly positive consensus ...
Redeye comments on Fortnox’s Q1, with the key figures matching our expectations.
Redeye comments on Waystream’s Q1 report, which managed to beat our estimates across the board.
As expected, Q1 is a modest quarter after an extended period of high organic growth.
Redeye comments on Lime’s Q1 report, with key figures missing our forecasts slightly.
Sales -3% vs. cons, adj. EBITA +21% vs. cons Announces growth initiatives & cost savings efforts Con...
Atria reported Q1 adjusted EBIT of EUR 12.8m, 31% (EUR 3.
Redeye updates its estimates and valuation following Vitec releasing its Q1 2025 report.
Report out 8 May at 08:00 CEST Q1e: sales of SEK 52m +37% y-o-y, adj.
